Oct 2026· Journal of Psychopharmacology· pp.
2698811261490205
· 0 citations· 70 references
Medicine
TL;DR
These findings support the hypothesis that targeting M1 and M4 receptors can rescue cocaine-induced cognitive symptoms and further support M1/M4 receptors as promising targets to treat CUD.
Abstract
Background
Cocaine use and cocaine use disorder (CUD) are increasing public health concerns that lack effective treatments. CUD is a chronic illness characterized by relapse, altered activity in the prefrontal cortex and neurocognitive symptoms. Pharmacologically stimulating muscarinic acetylcholine receptors M1 and/or M4 has been shown to counteract abuse-related effects of cocaine and, independently, to have pro-cognitive effects.
Objectives
We tested the hypotheses that (1) withdrawal from a subchronic cocaine regimen in mice will negatively impact attention and impulsivity and (2) pharmacological stimulation of M1, M4, or M1 + M4 receptors will blunt or reverse these cocaine-induced impairments.
Methods
Using a touchscreen rodent continuous performance test, male C57BL/6JRj mice were trained to respond to a target and withhold responses to a non-target stimulus. Mice received 20 mg/kg cocaine for 5 days and 30 mg/kg for 14 days. Then, the effect of treatment with the muscarinic M1 agonist VU0364572 (3.2 mg/kg) and the M4 PAM VU0152100 (1.8 mg/kg) was assessed in test probes challenging attention (variable stimulus duration) and impulsivity (variable intertrial interval), respectively.
Results
Cocaine exposure significantly and consistently impaired measures of attention (discriminability, accuracy), with less consistent effects on impulsivity (false alarm rate, premature responses). Treatment with combined VU0364572 + VU0152100 reversed cocaine-induced attention deficits, while each drug alone had little effect.
Conclusions
These findings support the hypothesis that targeting M1 and M4 receptors can rescue cocaine-induced cognitive symptoms. Because cognitive impairments are thought to contribute to relapse to cocaine use, these results further support M1/M4 receptors as promising targets to treat CUD.
Psychostimulant use disorders, particularly cocaine use disorder, is marked by compulsive drug seeking and high relapse rates. Cocaine blocks the dopamine transporter (DAT), preventing dopamine (DA) reuptake, leading to elevated DA signaling-a key driver of its addictive properties. Although behavioral interventions su...
Yi-Bin Xu, Stacia I. Lewandowski, Ejaaz R. Moazzam et al.· Journal of Pharmacology and...· 0 citations
Rationale Cocaine use disorder (CUD) remains without an FDA-approved pharmacotherapy, highlighting the need for novel mechanistically distinct targets. Prior work implicates neuromedin U (NMU) and its receptor NMU receptor 2 (NMUR2) in cocaine-directed behavior, but NMUR2 peptide-based approaches have limited translati...
V. Martinez, Hong Sun, Cun Zhang et al.· Research Square· 0 citations
Neural substrates playing a role in the development of sensitized behavioral responses after repeated methamphetamine exposure are not fully understood. In this study, we investigated the role of kappa opioid receptors (KORs) in the development of methamphetamine-induced locomotor sensitization, which is used as a rode...
Sarah L. Seeley, Madison Snyder, Manoranjan S. D'Souza· Behavioural Brain Research· 0 citations
Disruption of cerebral cortical interneuron maturation has been implicated in the pathophysiology of schizophrenia, and NMDA receptor antagonists are widely used to model psychosis-relevant behavioral phenotypes in rodents. Dopamine D2 receptors (D2Rs) are expressed on cortical GABAergic interneurons derived from the m...
Y. Thabet, Samantha E. Neville, Aisha O. Shafau et al.· Discover Neuroscience· 0 citations
Muscarinic acetylcholine receptor (mAChR) drugs have emerged as a promising new class of antipsychotics, highlighted by the FDA approval of Cobenfy, the first treatment for schizophrenia that does not directly target dopamine receptors. The M4 receptor subtype is thought to be a key mediator of antipsychotic-like effic...
Daniel Joyner, Curran Johnston, Yu-Min Choi et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.